Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12446486 | 0.78 | GFER (0.34) | CYP19A1 | |
| SCHEMBL28231871 | 0.72 | ADORA2A (0.46) | — | |
| SCHEMBL27820489 | 0.70 | KDM4E (0.53) | CYP19A1 | |
| SCHEMBL28232733 | 0.70 | KDM4E (0.59) | CYP19A1 | |
| SCHEMBL23525582 | 0.69 | CYP19A1 (0.47) | CYP19A1 | |
| SCHEMBL5252118 | 0.69 | HTR2B (0.53) | CYP19A1 | |
| SCHEMBL1995375 | 0.69 | HPGDS (0.59) | CYP19A1 | |
| SCHEMBL5252113 | 0.69 | CYP19A1 (0.47) | CYP19A1 | |
| SCHEMBL149587 | 0.68 | — | — | |
| SCHEMBL14736462 | 0.67 | CYP19A1 (0.45) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108373476-B | Kinase inhibitor and preparation and application thereof | 成都地奥制药集团有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-9271979-B2 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271980-B2 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2016-03-01 | — | — | US | disclosed |
| US-8618116-B2 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130040957-A1 | Deuterium-Enriched Pyrimidine Compounds and Derivatives | Dhanoa, Daljit Singh (US) | 2013-02-14 | — | — | US | disclosed |
| US-20120035191-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110028496-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DHANOA DALJIT SINGH | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028496-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DPYD, DHPS, DHODH | CYP19A1 1037/4885 |
| US-20120035191-A1 | Deuterium-enriched pyrimidine compounds and derivatives | DBH, OPRK1, PYGB | CYP19A1 989/4885 |
| US-20130040957-A1 | Deuterium-Enriched Pyrimidine Compounds and Derivatives | HTR2C, HTR2A, HTR5A | CYP19A1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.